Therapy of core binding factor acute myeloid leukemia: Incremental improvements toward better long-term results

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 2, 2013, Pages 153-158

  Bhatt, Vijaya Raj ^a,b   Kantarjian, Hagop ^a   Cortes, Jorge E ^a   Ravandi, Farhad ^a   Borthakur, Gautam ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

Chemotherapy; High dose cytarabine; Inversion (16); Response; Translocation (8; 21)

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MELPHALAN; MERCAPTOPURINE; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA; DRUG DOSE ESCALATION; DRUG MEGADOSE; FOLLOW UP; HUMAN; LONG TERM SURVIVAL; MAINTENANCE CHEMOTHERAPY; MEDLINE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; SALVAGE THERAPY; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 84877314816     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.11.006     Document Type: Article

References (54)

1. Y.L. Kwong, V. Chan, K.F. Wong Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21) Cancer 75 1995 821 825
2. K. Tobal, P.R. Johnson, M.J. Saunders Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission Br J Haematol 91 1995 104 108
3. J.C. Byrd, K. Mrózek, R.K. Dodge Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and Leukemia Group B (CALGB 8461) Blood 100 2002 4325 4336 (Pubitemid 35429670)
4. H.F. Fernandez, Z. Sun, X. Yao Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 361 2009 1249 1259
5. D. Grimwade, H. Walker, F. Oliver The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial The Medical Research Council adult and children's leukaemia working parties Blood 92 1998 2322 2333 (Pubitemid 28452973)
6. R.F. Schlenk, A. Benner, F. Hartmann Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial Leukemia 17 2003 1521 1528 (Pubitemid 36986953)
7. F.R. Appelbaum, K.J. Kopecky, M.S. Tallman The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations Br J Haematol 135 2006 165 173 (Pubitemid 44401613)
8. K. Mrózek, K. Heinonen, C.D. Bloomfield Clinical importance of cytogenetics in acute myeloid leukaemia Best Pract Res Clin Haematol 14 2001 19 47 (Pubitemid 32372400)
9. R.F. Schlenk, A. Benner, J. Krauter Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German acute myeloid leukemia intergroup J Clin Oncol 22 2004 3741 3750 (Pubitemid 41102131)
10. G. Marcucci, K. Mrózek, A.S. Ruppert Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a cancer and Leukemia Group B study J Clin Oncol 23 2005 5705 5717
11. H.J. Shin, H.J. Kim, S.K. Sohn Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment Jpn J Clin Oncol 40 2010 556 566
12. Y. Kuwatsuka, K. Miyamura, R. Suzuki Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes Blood 113 2009 2096 2103
13. T. Prébet, N. Boissel, S. Reutenauer Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup J Clin Oncol 27 2009 4747 4753
14. C.G. Allen, R.K. Hills, C.M. Evans Mutations in a large cohort of young adult patients with core binding factor acute myeloid leukemia: impact on outcome and the selection of patients for alternative treatment including transplantation in first complete remission ASH Annual Meeting Abstracts 118 2011 419
15. S. Nguyen, T. Leblanc, P. Fenaux A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML intergroup Blood 99 2002 3517 3523 (Pubitemid 34534517)
16. R.F. Schlenk, M.C. Pasquini, W.S. Pérez HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML intergroup and CIBMTR Biol Blood Marrow Transplant 14 2008 187 196
17. R. Cairoli, A. Beghini, G. Grillo Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study Blood 107 2006 3463 3468
18. P. Paschka, G. Marcucci, A.S. Ruppert Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a cancer and Leukemia Group B study J Clin Oncol 24 2006 3904 3911 (Pubitemid 46630738)
19. S. Schnittger, T.M. Kohl, T. Haferlach KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival Blood 107 2006 1791 1799 (Pubitemid 43289355)
20. S.H. Park, H.S. Chi, S.K. Min Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia Leuk Res 35 2011 1376 1383
21. J.A. Pollard, T.A. Alonzo, R.B. Gerbing Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML Blood 115 2010 2372 2379
22. G. Borthakur, E. Lin, N. Jain Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia Cancer 115 2009 3217 3221
23. S.A. Gustafson, P. Lin, S.S. Chen Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21) (q22;q22) but does not have a favorable outcome Am J Clin Pathol 131 2009 647 655
24. L. Bullinger, F.G. Rücker, S. Kurz Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia Blood 110 2007 1291 1300 (Pubitemid 47281428)
25. D.H. Yang, J.J. Lee, Y.C. Mun Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation Am J Hematol 82 2007 1 5
26. B. Löwenberg, G.J. Ossenkoppele, W. van putten High-dose daunorubicin in older patients with acute myeloid leukemia N Engl J Med 361 2009 1235 1248
27. V. Gandhi, E. Estey, M.J. Keating Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy J Clin Oncol 11 1993 116 124 (Pubitemid 23059984)
28. G. Borthakur, H. Kantarjian, X. Wang Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival Cancer 113 2008 3181 3185
29. A.K. Burnett, N.H. Russell, R.K. Hills Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia J Clin Oncol 30 2012 3924 3931
30. A.K. Burnett, R.K. Hills, D. Milligan Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial J Clin Oncol 29 2011 369 377
31. S. Castaigne, C. Pautas, C. Terré Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study Lancet 379 2012 1508 1516
32. G. Borthakur, E. Jabbour, X. Wang Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML) ASCO Meeting Abstracts 28 15 Suppl 2010 6552
33. C.D. Bloomfield, D. Lawrence, J.C. Byrd Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype Cancer Res 58 1998 4173 4179 (Pubitemid 28440576)
34. J.C. Byrd, R.K. Dodge, A. Carroll Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered J Clin Oncol 17 1999 3767 3775
35. J.C. Byrd, A.S. Ruppert, K. Mrozek Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv; 16(p13q22) or t(16;16)(p13;q22): results from CALGB 8461 J Clin Oncol 22 2004 1087 1094 (Pubitemid 41095042)
36. K.F. Bradstock, J.P. Matthews, R.M. Lowenthal A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine Blood 105 2005 481 488 (Pubitemid 40070725)
37. B. Löwenberg, T. Pabst, E. Vellenga Cytarabine dose for acute myeloid leukemia N Engl J Med 364 2011 1027 1036
38. J. Delaunay, N. Vey, T. Leblanc Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML intergroup Blood 102 2003 462 469 (Pubitemid 36841961)
39. N.C. Gorin, M. Labopin, F. Frassoni Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for blood and marrow transplantation J Clin Oncol 26 2008 3183 3188
40. A. de Labarthe, C. Pautas, X. Thomas Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia Bone Marrow Transplant 35 2005 767 773 (Pubitemid 40626698)
41. J. Koreth, R. Schlenk, K.J. Kopecky Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials JAMA 301 2009 2349 2361
42. M.L. Slovak, K.J. Kopecky, P.A. Cassileth Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a southwest Oncology Group/Eastern Cooperative Oncology Group study Blood 96 2000 4075 4083
43. N. Feller, M.A. van der Pol, A. van Stijn MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia Leukemia 18 2004 1380 1390 (Pubitemid 39136748)
44. W. Kern, D. Voskova, C. Schoch Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia Blood 104 2004 3078 3085 (Pubitemid 39517010)
45. A. Candoni, E. Toffoletti, R. Gallina Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia Clin Transplant 25 2011 308 316
46. G. Gianfaldoni, F. Mannelli, V. Ponziani Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia Haematologica 95 2010 833 836
47. H. Lapillonne, A. Renneville, A. Auvrignon High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia J Clin Oncol 24 2006 1507 1515 (Pubitemid 46638771)
48. A. Nowakowska-Kopera, T. Sacha, I. Florek Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia Leuk Lymphoma 50 2009 1326 1332
49. X.S. Zhao, S. Jin, H.H. Zhu Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT Bone Marrow Transplant 47 2012 499 507
50. A. Corbacioglu, C. Scholl, R.F. Schlenk Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia J Clin Oncol 28 2010 3724 3729
51. M. Weisser, C. Haferlach, W. Hiddemann The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors Leukemia 21 2007 1177 1182 (Pubitemid 46831805)
52. J.A. Yin, M.A. O'Brien, R.K. Hills Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial Blood 120 2012 2826 2835
53. M.R. O'Donnell, C.N. Abboud, J. Altman Acute myeloid leukemia J Natl Compr Cancer Netw 9 2011 280 317
54. H. Döhner, E.H. Estey, S. Amadori Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood 115 2010 453 474